A hydromorphone prolonged-release tablet (Jurnista®) was recently listed on the Pharmaceutical Benefits Scheme (PBS) schedule as a restricted benefit for chronic severe disabling cancer or non-cancer pain not responding to non-opioid analgesics. Jurnista® was listed after recommendation by the Pharmaceutical Benefits Advisory Committee on the basis of cost minimisation when compared with oxycodone controlled-release tablets, being no less effective and similarly priced.
Hydromorphone is an opioid which is approximately equivalent to five times the potency of morphine. Jurnista® has been formulated using the OROS® osmotic pump bilayer with a semi-permeable cellulose acetate coating that controls the rate at which water is absorbed into the tablet after swallowing. The drug is released from this system at a controlled rate by a laser-drilled hole in the tablet. Pharmacokinetic studies demonstrate that plasma concentrations reach a plateau within 6–8 hours after oral administration and then remain relatively constant until approximately 24 hours post-dose.
The complete bulletin can be downloaded here
The 2009 RGH E-Bulletins are archived here.
If you like this post and what else you see on the blog please subscribe by RSS feed (the orange button) or by email. Visit my subscription page.